CHRM2

The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine to these receptors and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The muscarinic cholinergic receptor 2 is involved in mediation of bradycardia and a decrease in cardiac contractility. Multiple alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Jul 2008]

Cholinergic Receptor Muscarinic 2

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.

Adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway Source: GO_Central
Adenylate cyclase-modulating G protein-coupled receptor signaling pathway Source: ProtInc
Chemical synaptic transmission Source: GO_Central
G protein-coupled acetylcholine receptor signaling pathway Source: UniProtKB
G protein-coupled receptor signaling pathway Source: Reactome
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger Source: GO_Central
Membrane organization Source: Reactome
Nervous system development Source: ProtInc
Phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway Source: ProtInc
Regulation of heart contraction Source: ProtInc
Regulation of smooth muscle contraction Source: GO_Central
Response to virus Source: UniProtKB

Cell membrane; Postsynaptic cell membrane. Phosphorylation in response to agonist binding promotes receptor internalization.

Major depressive disorder (MDD): A common psychiatric disorder. It is a complex trait characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes. A major depressive episode is characterized by at least 2 weeks during which there is a new onset or clear worsening of either depressed mood or loss of interest or pleasure in nearly all activities. Four additional symptoms must also be present including changes in appetite, weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts. The episode must be accompanied by distress or impairment in social, occupational, or other important areas of functioning.

Extracellular: 1-22
Helical: 23-45
Cytoplasmic: 46-59
Helical: 60-80
Extracellular: 81-97
Helical: 98-119
Cytoplasmic: 120-139
Helical: 140-162
Extracellular: 163-184
Helical: 185-209
Cytoplasmic: 210-387
Helical: 388-410
Extracellular: 411-418
Helical: 419-442
Cytoplasmic: 443-466

Phosphorylated in response to agonist treatment.